UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): July 3, 2007
ARADIGM
CORPORATION
(Exact
name of Registrant as specified in its charter)
|
California
|
|
0-28402
|
|
94-3133088
|
|
(State
or other jurisdiction of Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
3929
Point Eden Way
Hayward,
CA 94545
(Address
of Principal Executive Offices)
(510)
265-9000
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 — Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Norman
Halleen was appointed as the principal financial and accounting officer for
Aradigm Corporation (the “Company”) effective July 3, 2007 and as its Interim
Chief Financial Officer effective July 2, 2007. Mr. Halleen previously served
as
Aradigm's Vice President, Finance and Chief Financial Officer, and has more
than
two decades of senior-level financial and management experience, primarily
in
the healthcare industry.
Mr. Halleen,
age 54, served as Senior Vice President of Finance and Chief Financial Officer
of InterMune, Inc., a publicly traded biopharmaceutical company, from October
2004 to August 2006. Prior to joining InterMune, Mr. Halleen served as Vice
President, Finance and Chief Financial Officer of Syrrx, Inc., a privately
held
drug discovery company, from April 2001 to June 2003. Prior to Syrrx,
Mr. Halleen was the Company’s Vice President, Finance and Chief Financial
Officer from December 1999 to April 2001, and previously held the same positions
at Collagen Corporation, a publicly traded biomaterials and medical device
company, from January 1997 to October 1999. Mr. Halleen has also worked in
various financial consulting and executive positions in Hong Kong and the
United
States, including a ten-year tenure with Syntex Corporation. Mr. Halleen
holds an A.B. from Stanford University and an M.B.A. from the Harvard Graduate
School of Business
The
Company has entered into a consulting agreement with Mr. Halleen that provides
for a consulting fee of $22,500 per month and health care insurance that
includes medical, dental and vision coverage for the term of the consulting
agreement. Total annual compensation for services and health insurance will
not
exceed $300,000 without further approval.
The
consulting agreement is filed as exhibit 10.1 hereto.
Item 9.01
— Financial Statements and Exhibits.
|
10.1
|
Consulting
Agreement effective as of July 2, 2007 by and between the Company
and
Norman Halleen.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Dated:
July 10, 2007
| |
ARADIGM
CORPORATION
|
|
| |
|
|
| |
By:
|
/s/
Igor Gonda
|
|
| |
|
Igor
Gonda
|
|
| |
|
President
and Chief Executive Officer
|
|
EXHIBIT
INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
Consulting
Agreement effective as of July 2, 2007 by and between the Company
and
Norman Halleen.
|